| |
MammaPrint |
PAM 50
(Breast bioclassifiers) |
MapQuant Dx/simplified |
Oncotype DX |
Breast Cancer Index (HoxB13:IL17BR/MGI) |
| Analysis |
Microarray |
qRT-PCR |
Microarray/qRT-PCR |
qRT-PCR |
qRT-PCR |
| Provider |
Agendia
(Amsterdam, Netherlands) |
NanoString Technologies (Seattle, WA, USA) |
Ipsogen
(Marseille, France) |
Genomic Health
(Redwood City, CA, USA) |
bioTheranostics
(San Diego, CA, USA) |
| Assay |
70-gene signature |
50-gene signature |
97-gene signature or
8-gene PCR |
21-gene recurrence score |
Two-gene HOXB13:IL17R/ 5-gene molecular grade index |
| Tissue type |
Fresh or Frozen |
FFPE |
Fresh or Frozen or FFPE |
FFPE |
FFPE |
| Clinical indications |
• 0- 3 node positive
• < 5cm
• All ages
• ER+ or ER- |
•Stage I-III
•All ages
• ER+ or ER- |
•ER+
• Histologic grade 2 |
•ER+
• 0-3 node positive
•Treated with tamoxifen
•Post menopausal, treated with aromatase inhibitors (AI) |
•ER+
• Node negative
• All ages |
| Prognostic/ predictive value |
•Prognostic for early distant recurrence within first 5 year after diagnosis
•Predictive for chemoresponse in poor prognostic group |
•Prognostic based on assigned intrinsic molecular subtypes
•Predictive for
tamoxifen benefit in luminal cancers |
•Prognostic in ER+ tumors
• Predictive for chemoresponse in high GGI tumor |
•Prognostic for distant recurrence in 10 years
•Predictive for chemoresponse in high recurrence score group |
•Prognostic in ER+ tumors
•Predictive for tamoxifen response in low risk group |
